Bright Minds Biosciences Inc.(DRUG)Earnings, Financials & Key Ratios
DRUG•NASDAQ
$88.90
$865M mkt cap·Price updated May 6, 2026
AboutBright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$14M
- Net Income-$12M-336.5%
- EPS (Diluted)-1.28-96.9%
- ROE-27.93%+39.5%
- Debt/Equity0.00-92.9%
- Interest Coverage-541.45
DRUG Key Insights
Bright Minds Biosciences Inc. (DRUG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 83 (top 17%)
✗Weaknesses
- ✗Shares diluted 59.6% in last year
- ✗Expensive at 10.1x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DRUG Price & Volume
Bright Minds Biosciences Inc. (DRUG) stock price & volume — 10-year historical chart
Loading chart...
DRUG Growth Metrics
Bright Minds Biosciences Inc. (DRUG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-296.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-155.02%
Return on Capital
10 Years-91.25%
5 Years-68.45%
3 Years-52.81%
Last Year-31.8%
DRUG Recent Earnings
Bright Minds Biosciences Inc. (DRUG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (100%)
Q1 2026Latest
Feb 12, 2026EPS
$0.70
Est $0.98
+28.6%
Revenue
—
Q4 2025
Dec 23, 2025EPS
$0.41
Est $0.56
+27.1%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.53
Est $0.59
+10.2%
Revenue
—
Q1 2025
Feb 13, 2025EPS
$0.01
Est $0.23
+104.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 12, 2026 | $0.70vs $0.98+28.6% | — |
| Q4 2025 | Dec 23, 2025 | $0.41vs $0.56+27.1% | — |
| Q3 2025 | Aug 14, 2025 | $0.53vs $0.59+10.2% | — |
| Q1 2025 | Feb 13, 2025 | $0.01vs $0.23+104.3% | — |
Based on last 12 quarters of dataView full earnings history →
DRUG Peer Comparison
Bright Minds Biosciences Inc. (DRUG) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare DRUG vs Peers
Bright Minds Biosciences Inc. (DRUG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DRUG Income Statement
Bright Minds Biosciences Inc. (DRUG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 55.19K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -55.19K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 236.15K | 474.93K | 8.62M | 14.73M | 7.2M | 2.62M | 9.93M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 110.12K | 120.07K | 2.31M | 2.55M | 2.2M | 1.44M | 2.57M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 126.03K | 354.85K | 6.31M | 12.18M | 5M | 1.18M | 7.96M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -597.85K |
| Operating Income | -236.15K▲ 0% | -474.93K▼ 101.1% | -8.62M▼ 1715.7% | -14.73M▼ 70.8% | -7.2M▲ 51.1% | -2.62M▲ 63.7% | -13.94M▼ 432.7% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -101.11% | -1715.68% | -70.84% | 51.13% | 63.66% | -432.65% |
| EBITDA | 0 | 0 | 0 | -14.73M | -7.13M | 0 | -13.88M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | - | - | 51.6% | 100% | - |
| D&A (Non-Cash Add-back) | 236.15K | 474.93K | 8.62M | 6.04K | 72.45K | 2.62M | 55.19K |
| EBIT | -236.15K | -474.93K | -8.65M | -14.73M | -7.35M | -2.62M | -8.75M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 21.19K | 1.07M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 21.19K | 1.09M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 25.74K |
| Other Income/Expense | 0 | -5.45K | -27.64K | -232.93K | -172.46K | -185.31K | 1.71M |
| Pretax Income | -236.15K▲ 0% | -480.38K▼ 103.4% | -8.65M▼ 1700.8% | -14.96M▼ 73.0% | -7.37M▲ 50.7% | -2.8M▲ 62.0% | -12.23M▼ 336.5% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -236.15K▲ 0% | -480.38K▼ 103.4% | -8.65M▼ 1700.8% | -14.96M▼ 73.0% | -7.37M▲ 50.7% | -2.8M▲ 62.0% | -12.23M▼ 336.5% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -103.42% | -1700.83% | -72.99% | 50.74% | 61.99% | -336.46% |
| Net Income (Continuing) | -236.15K | -480.38K | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06▲ 0% | -0.38▼ 517.9% | -4.74▼ 1147.4% | -6.15▼ 29.7% | -1.98▲ 67.8% | -0.65▲ 67.2% | -1.28▼ 96.9% |
| EPS Growth % | - | -517.89% | -1147.37% | -29.75% | 67.8% | 67.17% | -96.92% |
| EPS (Basic) | -0.06 | -0.38 | -4.74 | -6.15 | -1.98 | -0.65 | -1.28 |
| Diluted Shares Outstanding | 1.28M | 1.28M | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M |
| Basic Shares Outstanding | 1.28M | 1.28M | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
DRUG Balance Sheet
Bright Minds Biosciences Inc. (DRUG) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 79.99K | 878.22K | 20.04M | 11.95M | 6.81M | 5.99M | 84.31M |
| Cash & Short-Term Investments | 79.99K | 799.93K | 19.76M | 11.63M | 6.75M | 5.72M | 82.91M |
| Cash Only | 79.99K | 799.93K | 19.76M | 11.63M | 6.75M | 5.72M | 82.91M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 61.93K |
| Accounts Receivable | 0 | 0 | 110.15K | 155.78K | 0 | 50.22K | 413.07K |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 83.98K | 2K | 2K | 138.86K | 66.41K | 117.66K | 111.97K |
| Property, Plant & Equipment | 0 | 0 | 0 | 138.86K | 66.41K | 117.66K | 80.39K |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 2K | 2K | 0 | 0 | 0 | 0 |
| Intangible Assets | 2K | 2 | 2 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 81.98K | 1K | 33.68K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | -1K | -33.68K | 0 | 0 | 0 | 31.57K |
| Total Assets | 163.97K▲ 0% | 880.22K▲ 436.8% | 20.04M▲ 2176.8% | 12.09M▼ 39.7% | 6.88M▼ 43.1% | 6.1M▼ 11.3% | 84.42M▲ 1282.9% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 436.81% | 2176.76% | -39.69% | -43.09% | -11.26% | 1282.92% |
| Total Current Liabilities | 36.71K | 150.92K | 638.57K | 1.47M | 280.86K | 528.68K | 2.34M |
| Accounts Payable | 36.71K | 138.42K | 596.57K | 1.25M | 182.31K | 407.55K | 1.71M |
| Days Payables Outstanding | - | - | - | - | - | - | 11.31K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 60.69K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -60.69K |
| Current Ratio | 2.18x | 5.82x | 31.38x | 8.11x | 24.26x | 11.32x | 36.10x |
| Quick Ratio | 2.18x | 5.82x | 31.38x | 8.11x | 24.26x | 11.32x | 36.10x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 71.98K | 0 | 39.58K | 41.25K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 71.98K | 0 | 39.58K | 41.25K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 36.71K | 150.92K | 638.57K | 1.54M | 280.86K | 568.26K | 2.38M |
| Total Debt | 0 | 0 | 0 | 139.91K | 73.55K | 118.96K | 125.78K |
| Net Debt | -79.99K | -799.93K | -19.76M | -11.49M | -6.67M | -5.6M | -82.78M |
| Debt / Equity | - | - | - | 0.01x | 0.01x | 0.02x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -541.45x |
| Total Equity | 127.26K▲ 0% | 729.29K▲ 473.1% | 19.4M▲ 2560.4% | 10.54M▼ 45.7% | 6.6M▼ 37.4% | 5.54M▼ 16.1% | 82.04M▲ 1381.9% |
| Equity Growth % | - | 473.06% | 2560.36% | -45.66% | -37.41% | -16.09% | 1381.93% |
| Book Value per Share | 0.10 | 0.57 | 10.81 | 4.27 | 1.77 | 1.28 | 11.93 |
| Total Shareholders' Equity | 127.26K | 729.29K | 19.4M | 10.54M | 6.6M | 5.54M | 58.91M |
| Common Stock | 205.98K | 980.66K | 27.08M | 32.24M | 33.91M | 35.42M | 88.49M |
| Retained Earnings | -78.72K | -559.09K | -9.21M | -24.17M | -31.55M | -34.35M | -33.44M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -81.98K | 161.3K | 1.57M | 2.48M | 3.4M | 4.01M | 3.86M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRUG Cash Flow Statement
Bright Minds Biosciences Inc. (DRUG) cash flow — operating, investing & free cash flow history
| Line item | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -42.01K | -288.39K | -7.32M | -13.59M | -7.02M | -1.85M | -6.24M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -586.5% | -2437.97% | -85.63% | 48.3% | 73.66% | -237.29% |
| Net Income | -78.72K | -480.38K | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M |
| Depreciation & Amortization | 0 | 0 | 0 | 6.04K | 72.45K | 73.36K | 76.87K |
| Stock-Based Compensation | 0 | 161.3K | 880.62K | 875.06K | 1.15M | 839.77K | 3.18M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 110.12K | 161.3K | 144.76K | -229.57K | 65.1K | -1.18K | 2.33M |
| Working Capital Changes | 36.71K | 30.68K | 306.08K | 726.31K | -941.72K | 39.81K | 398.49K |
| Change in Receivables | 0 | 0 | -110.15K | -45.63K | 0 | 0 | -260.52K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 5 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 122K | 1.01M | 26.06M | 5.2M | 2.19M | 810.57K | 61.44M |
| Debt Issued (Net) | 0 | 0 | 0 | -7.16K | -86.11K | -89.73K | -100.15K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 900K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 366K | 0 | -1.69M | 1.17M | 1.06M | 302 | 28.24K |
| Net Change in Cash | 79.99K▲ 0% | 719.94K▲ 800.0% | 18.96M▲ 2533.6% | -8.13M▼ 142.9% | -4.88M▲ 40.0% | -1.03M▲ 78.9% | 55.3M▲ 5480.2% |
| Free Cash Flow | -42.01K▲ 0% | -288.39K▼ 586.5% | -7.32M▼ 2438.0% | -13.59M▼ 85.6% | -7.02M▲ 48.3% | -1.85M▲ 73.7% | -6.24M▼ 237.3% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -586.5% | -2437.97% | -85.63% | 48.3% | 73.66% | -237.29% |
| FCF per Share | -0.03 | -0.23 | -4.08 | -5.50 | -1.89 | -0.43 | -0.91 |
| FCF Conversion (FCF/Net Income) | 0.18x | 0.60x | 0.85x | 0.91x | 0.95x | 0.66x | 0.51x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRUG Key Ratios
Bright Minds Biosciences Inc. (DRUG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -185.56% | -112.16% | -85.94% | -99.95% | -86.02% | -46.18% | -27.93% |
| Debt / Equity | - | - | - | 0.01x | 0.01x | 0.02x | 0.00x |
| Interest Coverage | - | - | - | - | - | - | -541.45x |
| FCF Conversion | 0.18x | 0.60x | 0.85x | 0.91x | 0.95x | 0.66x | 0.51x |
DRUG Frequently Asked Questions
Bright Minds Biosciences Inc. (DRUG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bright Minds Biosciences Inc. (DRUG) grew revenue by 0.0% over the past year. Growth has been modest.
Bright Minds Biosciences Inc. (DRUG) reported a net loss of $11.1M for fiscal year 2025.
Dividend & Returns
Bright Minds Biosciences Inc. (DRUG) has a return on equity (ROE) of -27.9%. Negative ROE indicates the company is unprofitable.
Bright Minds Biosciences Inc. (DRUG) had negative free cash flow of $8.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More DRUG
Bright Minds Biosciences Inc. (DRUG) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates